Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These gastrointestinal adverse events are poorly documented in the literature due to their low frequency [6].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial gastrointestinal side effects were reported by approximately 30% of participants, which were generally mild to moderate in severity and significantly diminished during sustained treatment achieved through dose titration, resulting in a discontinuation rate of less than 8% [87].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation. Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher doses are more likely to provoke these adverse symptoms, indicating a dose‐dependent relationship [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because dietary lipids act synergistically with GLP-1 to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [66]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global clinical measure of fitness and frailty in elderly people
Rockwood, K. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050051 · Cited by 8,968 · cited 1×
“The Clinical Frailty Scale may sometimes be useful to guide dose adjustment [75].”
MethodLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“CKD increases the risk of GLP-1 RA-associated diarrhoea, with symptoms being more severe with albuminuria [84].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
BackgroundResultSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney di…”
ResultDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · cited 1×
“Sarcopenia risk must be assessed before and during GLP-1 RA treatment since the sharp weight loss in the elderly may be in part at the expense of lean mass [80,81].”
BackgroundBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“It is worth mentioning that long-acting agents have been associated with less nausea and vomiting but with more diarrhoea [30], which might be explained by a more sustained effect of these compounds on GLP-1 intestinal receptors [31].”
BackgroundHe, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356 · cited 1×
“Higher GLP-1 RA doses and, especially, the duration of treatment influenced the risk [61].”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296 · cited 1×
“<1% with placebo), according to clinical trial programs [9,15,18].”
BackgroundSemaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288 · cited 1×
“In people with obesity, the incidence of gallbladder-related events was always <3% [10,54].”
BackgroundMeier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262 · cited 1×
“, to avoid excessive delay in gastric emptying upon treatment with GLP-1 RAs, especially with the long-acting ones [37,38].”
BackgroundLi, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254 · cited 1×
“Another one covering 55 randomized controlled trials and five observational studies with more than 300,000 participants, drew the same conclusion [60].”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254 · cited 1×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
ResultEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248 · cited 1×
“GLP-1 RAs have occasionally been described to exacerbate its symptoms, possibly because of the transient delay in gastric emptying subsequent to treatment initiation [78,79].”
BackgroundWharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236 · cited 7×
“If drugs to mitigate nausea (or other GI AEs) are needed for over a month when the maintenance GLP-1 RA dose has been reached, a dose reduction should be considered for the patient to tolerate the drug with no need for pharmacological support [35].”
BackgroundInfluentialYamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228
Blonde, L., & Russell‐Jones, D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227
Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224 · cited 1×
“GLP-1 RAs have occasionally been described to exacerbate its symptoms, possibly because of the transient delay in gastric emptying subsequent to treatment initiation [78,79].”
BackgroundYabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200 · cited 6×
“Symptoms have been reported to last for about three days in people with obesity treated with GLP-1 RA [18].”
BackgroundInfluentialJendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155 · cited 1×
“A meta-analysis that included studies lasting for ≥24 months, with more than 9000 patients treated with GLP-1 RA during such period, did not find an association between GLP-1 RA therapy and AP either [59].”
MethodKaragiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Wharton, S., Kuk, J. L., Luszczynski, M., Kamran, E., & Christensen, R. A. G. (2019) · Clinical Obesity · doi:10.1111/cob.12323 · Cited by 144 · cited 1×
“Accordingly, real-world series confirmed that constipation occurs more frequently in patients with overweight/obesity than with T2D [50].”
BackgroundEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130 · cited 1×
“Comment Semaglutide exposure is not influenced by renal impairment [83], and thus it is a suitable choice for T2D patients with CKD and obesity.”
BackgroundSafety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 130 · cited 1×
“A comprehensive review encompassing 30 trials focusing on GLP-1 RA safety in people with T2D concluded that the risk of gallbladder complications or acute pancreatitis (AP) associated with this medication was generally low [53].”
BackgroundHonigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125 · cited 1×
“Although, as said above, weight loss induced by GLP-1 RAs comes mainly from reductions in fat mass rather than lean mass, nutritional advice and exercise programmes to achieve muscle strengthening are recommended to minimize sarcopenic risk [74].”
BackgroundRobert, S. A., Ghani, R. A., Shah, S. A., Chinna, K., Mohamud, W. N. W., & Kamaruddin, N. A. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.03.005 · Cited by 115
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93
Kostev, K., Ouwens, M., Grandy, S., Johnsson, K. M., & Qiao, Q. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99732 · Cited by 92
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Zhang, X., Zhao, Y., Chen, S., & Shao, H. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12838 · Cited by 92
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12837 · Cited by 89
Treatment of obesity in older persons—A systematic review
Haywood, C., & Sumithran, P. (2019) · Obesity Reviews · doi:10.1111/obr.12815 · Cited by 84 · cited 1×
“Sarcopenia risk must be assessed before and during GLP-1 RA treatment since the sharp weight loss in the elderly may be in part at the expense of lean mass [80,81].”
BackgroundChao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22653 · Cited by 84
Da Porto, A., Casarsa, V., Colussi, G., Catena, C., Cavarape, A., & Sechi, L. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.009 · Cited by 80
Steinberg, W. M., Rosenstock, J., Wadden, T. A., Donsmark, M., Jensen, C. B., & DeVries, J. H. (2017) · Diabetes Care · doi:10.2337/dc16-2684 · Cited by 76 · cited 2×
“Finally, although higher circulating levels of lipase and amylase were reported in patients on GLP-1 RA therapy in many trials, the increases were rarely higher than three or five-fold the upper limit of normal (ULN), respectively [9–17], returned to normal levels after medication withdrawn, and were poor predictors o…”
BackgroundSwitching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74 · cited 1×
“In fact, the switching strategy has already been proposed in the context of the treatment of people with T2D [40,41].”
BackgroundActions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73 · cited 1×
“It is worth mentioning that long-acting agents have been associated with less nausea and vomiting but with more diarrhoea [30], which might be explained by a more sustained effect of these compounds on GLP-1 intestinal receptors [31].”
BackgroundDong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001706 · Cited by 71 · cited 1×
“A study performed to assess whether or not there was a direct association between GI AEs and the extent of weight loss concluded that weight loss was largely independent of GI AEs [47,64].”
BackgroundHunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65 · cited 1×
“Furthermore, preliminary data suggest that these compounds might play a beneficial role in intestinal diseases [77].”
BackgroundGrimm, M., Han, J., Weaver, C., Griffin, P., Schulteis, C. T., Dong, H., & Malloy, J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2660 · Cited by 63 · cited 2×
“Diarrhoea initiates during the first four weeks of treatment, after which the incidence notably decreases [15,49].”
BackgroundUzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 62
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
Keller, J., Trautmann, M. E., Haber, H., Tham, L. S., Hunt, T., Mace, K., & Linnebjerg, H. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.005 · Cited by 61
Exenatide-Induced Acute Pancreatitis
Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09104.crr · Cited by 58 · cited 1×
“HCPs must be aware of the possibility of these rare side effects to act early and avoid the complications related to volume depletion, such as severe renal failure [62,63].”
BackgroundDu, Y., Su, T., Song, X., Gao, J., Zou, D., Zuo, C., Xie, W.-F., Wang, B., Zhang, Z., Xu, J., et al. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000033 · Cited by 51 · cited 1×
“Among substituted benzamides, cinitapride may be an alternative to metoclopramide [48].”
BackgroundNexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51
Alterations in energy balance following exenatide administration
Bradley, D. P., Kulstad, R., Racine, N., Shenker, Y., Meredith, M., & Schoeller, D. A. (2012) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h2012-068 · Cited by 47
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 45
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 44 · cited 1×
“In fact, the switching strategy has already been proposed in the context of the treatment of people with T2D [40,41].”
BackgroundArd, J., Cannon, A., Lewis, C. E., Lofton, H., Vang Skjøth, T., Stevenin, B., & Pi‐Sunyer, X. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12632 · Cited by 43
Aviles Bueno, B., Soler, M. J., Perez-Belmonte, L., Jimenez Millan, A., Rivas Ruiz, F., & Garcia de Lucas, M. D. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac096 · Cited by 43
Self-citationManagement of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41 · cited 1×
“to oral semaglutide or vice versa, may be an option [42].”
BackgroundReal‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgeles, J. R., García, H., & Pereg, V. (2019) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.51 · Cited by 38
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38 · cited 1×
“• If GI AEs appear during the dose-escalating phase, HCPs could modify the planned schedule by implementing one or several of the following points [35,36]:”
BackgroundAroda, V. R., Bauer, R., Christiansen, E., Haluzík, M., Kallenbach, K., Montanya, E., Rosenstock, J., & Meier, J. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14710 · Cited by 38
Ellero, C., Han, J., Bhavsar, S., Cirincione, B. B., DeYoung, M. B., Gray, A. L., Yushmanova, I., & Anderson, P. W. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03085.x · Cited by 35 · cited 4×
“Domperidone should be used rather than metoclopramide, as explained above [47].”
BackgroundInfluentialMody, R., Yu, M., Nepal, B., Konig, M., & Grabner, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14195 · Cited by 35
Rea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 33
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation
Yu, M. B., Xie, J., Landó, L. F., Kabul, S., & Swindle, R. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.017 · Cited by 32
Hong, J.-Y., Park, K.-Y., Kim, B.-J., Hwang, W.-M., Kim, D.-H., & Lim, D.-M. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.80 · Cited by 32
Approach to Obesity in the Older Population
Buch, A., Marcus, Y., Shefer, G., Zimmet, P., & Stern, N. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab359 · Cited by 31
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31 · cited 1×
“As a result, the risk of progression to T2D decreases, and improvements in lipid profile, blood pressure or sleep apnoea have been observed [3].”
BackgroundFitch, A., & Ingersoll, A. B. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1845534 · Cited by 26 · cited 2×
“4–5 weeks of treatment, when gastric emptying is more significantly delayed [45], decreasing thereafter [9–17].”
BackgroundDi Loreto, C., Minarelli, V., Nasini, G., Norgiolini, R., & Del Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 21
Meier, J. J., Granhall, C., Hövelmann, U., Navarria, A., Plum‐Mörschel, L., Ramesh, C. K., Tannapfel, A., & Kapitza, C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14632 · Cited by 19 · cited 1×
“All of the AEs were mild-to-moderate, with no withdrawals because of them [76].”
BackgroundFernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Kaur, P., Mishra, S., Mithal, A., Saxena, M., Makkar, A., & Sharma, P. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.126572 · Cited by 17 · cited 2×
“Nausea Real-world studies confirm that nausea is the most frequent GI AE that arises upon initiation of GLP-1 RA [20,43,44].”
BackgroundSvensson, A., Toll, A., Lebrec, J., Miftaraj, M., Franzén, S., & Eliasson, B. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14276 · Cited by 17
Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
Morillas, C., D’Marco, L., Puchades, M. J., Solá-Izquierdo, E., Górriz-Zambrano, C., Bermúdez, V., & Górriz, J. L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105388 · Cited by 16 · cited 2×
“Despite GI AEs may be frequent in the first weeks, attempts to alleviate symptoms are worthwhile: withdrawal risk decreases; thus, patients benefit from cardiorrenal protection and efficient metabolic control, which may allow reducing the intensity of insulin treatment, thus minimizing hypoglycaemia risk [82].”
BackgroundSelf-citationPatient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16 · cited 1×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
ResultFeng, W., Wang, W., Meng, R., Wu, G., Zhang, M., Zhang, X., Yin, H., & Zhu, D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002290 · Cited by 11
Tanaka, K., Okada, Y., Tokutsu, A., & Tanaka, Y. (2022) · Scientific Reports · doi:10.1038/s41598-021-04149-z · Cited by 11
Bellido, D., Galiana, P. A., Palomar, J. M. R., Sintes, R. A., Nubiolae, A., Bellido, V., & Romero, G. Z. (2018) · Current Therapeutic Research · doi:10.1016/j.curtheres.2018.09.001 · Cited by 7
Liraglutida en el tratamiento de la diabetes tipo 2:
Ampudia‐Blasco, F. J., Gómez, C. C., Cos, X., Alegría, J. G., Gimeno, E. J., Bravo, J. J. M., Raya, P. M., Pérez, J. N., & Puig‐Domingo, M. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)64003-3 · Cited by 5
Research works printed but not linked: 2
- 2010, Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach, Av. Diabetol., 26, 226
- 2014, Pancreatitis aguda severa y precoz por liraglutide, Arch. Med. Int., 36, 119
Cited by
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501006 · Cited by 416
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation; and tend to decrease in frequency and severity with continuation of a stable dose [38].”
Influential
Metadata
- Authors
- Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á.
- Affiliations
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
- Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain
- Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain
- Hospital Universitario La Paz (ES)
- Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain
- Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Madrid Health Service (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Universitat de València (ES)
- Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-12-24
- Volume
- 12
- Issue
- 1
- Pages
- 145
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9821052
- OpenAlex
- W4313260808
- Cited by
- 358
- References
- 83
- Citations by year
- 2026: 137 · 2025: 140 · 2024: 63 · 2023: 18
- FWCI
- 40.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Novo-Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, type 2 diabetes, obesity, dose escalation, maintenance dose, treatment discontinuation, glycemic control, weight loss, patient education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.